EU-Approval obtained for ZEJULA (R) (Niraparib) that is used for treating Patients with recurrent Ovarian Cancer

首页> 外文期刊>Oncology research and treatment. >EU-Approval obtained for ZEJULA (R) (Niraparib) that is used for treating Patients with recurrent Ovarian Cancer

【24h】

EU-Approval obtained for ZEJULA (R) (Niraparib) that is used for treating Patients with recurrent Ovarian Cancer

机译：用于Zejula（R）（Niraparib）的欧盟批准用于治疗卵巢癌症的患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2018年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Effects of DC-CIK cell immunotherapy combined with chemotherapy on immune function, coagulation function and tumor stem cell markers in patients with recurrent ovarian cancer [J] . Jia-Li Wu, Yan-Ning Fang, Hong Li 海南医科大学学报（英文版） . 2017,第023期
2. Effects of DC-CIK cell immunotherapy combined with chemotherapy on immune function, coagulation function and tumor stem cell markers in patients with recurrent ovarian cancer [J] . Jia-Li Wu, Yan-Ning Fang, Hong Li 海南医科大学学报(英文版) . 2017,第023期
3. Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer [J] . Keng Shen, Zhilan Peng, Beihua Kong, 癌症生物学与医学（英文版） . 2009,第006期
4. TREATMENT OPTIONS FOR PATIENTS WITH RECURRENT OVARIAN CANCER：A REVIEW OF 54 CASES [J] . Ying, Jin, Ling-ya, 中国医学科学杂志：英文版 . 2006,第001期
5. EU-Approval obtained for ZEJULA (R) (Niraparib) that is used for treating Patients with recurrent Ovarian Cancer [J] . Oncology research and treatment. . 2018,第1a2期

机译：用于Zejula（R）（Niraparib）的欧盟批准用于治疗卵巢癌症的患者
6. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial [J] . Mirza Mansoor R., Benigno B., Dorum A., Gynecologic Oncology: An International Journal . 2020,第2期

机译：用Niraparib与安慰剂治疗的经常性卵巢癌患者的长期安全：III期engot-OV16 / Nova试验的结果
7. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial [J] . Oza Amit M., Matulonis Ursula A., Malander Susanne, The lancet oncology . 2018,第8期

机译：用Niraparib与安慰剂（engot-OV16 / Nova）治疗的经常性卵巢癌患者的生活质量：双盲，第3期，随机对照试验结果
8. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
9. Development of Novel Approaches for the Treatment of Recurrent Ovarian Cancer [D] . Mohammadali Pourmalekshah, Obeid. 2020

机译：新型卵巢癌治疗新方法的发展
10. Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib [O] . Junjian Wang, Jianqing Zhu 2021

机译：用尼拉帕里布的个性化起始剂量治疗中国晚期卵巢癌患者的现实世界血液学不良事件
11. Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial [O] . A.M. Oza, U.A. Matulonis, S. Malander, 2017

机译：用Niraparib治疗的经常性卵巢癌（OC）患者的生活质量：engot-OV16 / Nova试验的结果
12. Role of Cyclin E and its Lower Molecular Forms in the Oncogenesis of Ovarian Cancer and its Predictive Value in Patients with Early Stage Ovarian Tumor [R] . Keyomarsi, K. 2007

机译：Cyclin E及其低分子形式在卵巢癌发生中的作用及其对早期卵巢肿瘤的预测价值

EU-Approval obtained for ZEJULA (R) (Niraparib) that is used for treating Patients with recurrent Ovarian Cancer

著录项

相似文献

相关主题

期刊订阅